Advertisement

Index by author

August 01, 1995; Volume 274,Issue 2

A

  1. Abete, P

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  2. Ahern, G P

    1. Blockade of a resting potassium channel and modulation of synaptic transmission by ecstasy in the hippocampus.
      L S Premkumar and G P Ahern
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 718-722;

  3. Akkermans, L M

    1. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon.
      M R Briejer, G J Veen, L M Akkermans, R A Lefebvre and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 641-648;

  4. Akunne, H C

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  5. Albuquerque, E X

    1. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current.
      M Alkondon and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 771-782;

  6. Alkondon, M

    1. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current.
      M Alkondon and E X Albuquerque
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 771-782;

  7. Ambrosio, G

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  8. Anderson, J J

    1. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
      J J Anderson, S Randall and T N Chase
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 928-936;

  9. Ansay, M

    1. Endogenous nitric oxide modulates acetylcholine-induced edema and vasoconstriction in isolated perfused rabbit lungs.
      A Delaunois, P Gustin and M Ansay
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 559-597;

  10. ANSAY, M.

    1. Endogenous Nitric Oxide Modulates Acetylcholine-induced Edema and Vasoconstriction in Isolated Perfused Rabbit Lungs
      A. DELAUNOIS, P. GUSTIN and M. ANSAY
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 589-597;

  11. Aretha, C W

    1. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors.
      C W Aretha, A Sinha and M P Galloway
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 609-613;

  12. Argentieri, T M

    1. Acute administration of 17 beta-estradiol inhibits calcium currents in isolated guinea pig detrusor myocytes.
      J H Sheldon and T M Argentieri
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 723-729;

  13. Ashforth, E I

    1. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
      E I Ashforth, D J Carlile, R Chenery and J B Houston
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 761-766;

B

  1. Ban, K

    1. Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.
      F Ueda, K Ban and T Ishima
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 815-819;

  2. Barjavel, M J

    1. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
      F Stain, M J Barjavel, P Sandouk, M Plotkine, J M Scherrmann and H N Bhargava
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 852-857;

  3. Barrett, J E

    1. Modification of the behavioral effects of (+/-)BAY k 8644, cocaine and d-amphetamine by L-type calcium channel blockers in squirrel monkeys.
      S Rosenzweig-Lipson and J E Barrett
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 842-851;

  4. Barron, E

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  5. Barry, S

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  6. Bemis, K

    1. Pharmacological analysis of the noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat.
      H Danuser, K Bemis and K B Thor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 820-825;

  7. Bennett, G J

    1. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats.
      W H Xiao and G J Bennett
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 666-672;

  8. Bernstein, D

    1. Colchicine and cytochalasin B enhance cyclic AMP accumulation via postreceptor actions.
      J R Jasper, S R Post, K H Desai, P A Insel and D Bernstein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 937-942;

  9. Bhargava, H N

    1. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
      F Stain, M J Barjavel, P Sandouk, M Plotkine, J M Scherrmann and H N Bhargava
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 852-857;

  10. Blower, P

    1. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
      S Milano, P Blower, D Romain and L Grélot
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 951-961;

  11. Borrelli, A R

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  12. Bose, R

    1. Effects of phenamil on potassium and calcium channels of guinea pig ventricular myocytes.
      A Guia, N Leblanc and R Bose
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 649-656;

  13. Boucher, J L

    1. Nitric oxide formation during the cytochrome P-450-dependent reductive metabolism of 18-nitro-oxyandrostenedione.
      M Delaforge, A Piffeteau, J L Boucher and A Viger
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 634-640;

  14. Bowyer, J F

    1. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects.
      P Clausing, B Gough, R R Holson, W Slikker and J F Bowyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 614-621;

  15. Briejer, M R

    1. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon.
      M R Briejer, G J Veen, L M Akkermans, R A Lefebvre and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 641-648;

  16. Brink, C

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

  17. Bronstein, D M

    1. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality.
      D M Bronstein and J S Hong
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 943-950;

  18. Bruin, J

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  19. Bullock, A E

    1. Sodium channel blockers partially inhibit nicotine-stimulated 86Rb+ efflux from mouse brain synaptosomes.
      M J Marks, A E Bullock and A C Collins
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 833-841;

  20. Bunney, B S

    1. Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons.
      W X Shi, P Nathaniel and B S Bunney
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 735-740;

  21. Butelman, E R

    1. Effects of morphine and ketorolac on thermal allodynia induced by prostaglandin E2 and bradykinin in rhesus monkeys.
      S S Negus, E R Butelman, M B Gatch and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 805-814;

C

  1. Caccese, P

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  2. Carlile, D J

    1. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
      E I Ashforth, D J Carlile, R Chenery and J B Houston
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 761-766;

  3. Carlisle, M A

    1. Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats.
      M A Carlisle, D D Smyth and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 598-601;
    2. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats.
      G B Glavin, M A Carlisle and D D Smyth
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 741-744;

  4. Chase, T N

    1. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
      J J Anderson, S Randall and T N Chase
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 928-936;

  5. Chenery, R

    1. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
      E I Ashforth, D J Carlile, R Chenery and J B Houston
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 761-766;

  6. Chiariello, M

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  7. Christoffersen, C L

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  8. Cirillo, P

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  9. Clausing, P

    1. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects.
      P Clausing, B Gough, R R Holson, W Slikker and J F Bowyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 614-621;

  10. Collins, A C

    1. Sodium channel blockers partially inhibit nicotine-stimulated 86Rb+ efflux from mouse brain synaptosomes.
      M J Marks, A E Bullock and A C Collins
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 833-841;

  11. Colombo, P

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  12. Colton, M D

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

  13. Cooke, L W

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  14. Corbin, A E

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  15. Cregan, E C

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

D

  1. Danuser, H

    1. Pharmacological analysis of the noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat.
      H Danuser, K Bemis and K B Thor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 820-825;

  2. Davis, M D

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  3. Davis, T P

    1. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.
      S M Waters, C S Konkoy and T P Davis
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 783-789;

  4. de Boer, J

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  5. Delaforge, M

    1. Nitric oxide formation during the cytochrome P-450-dependent reductive metabolism of 18-nitro-oxyandrostenedione.
      M Delaforge, A Piffeteau, J L Boucher and A Viger
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 634-640;

  6. Delaunois, A

    1. Endogenous nitric oxide modulates acetylcholine-induced edema and vasoconstriction in isolated perfused rabbit lungs.
      A Delaunois, P Gustin and M Ansay
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 559-597;

  7. DELAUNOIS, A.

    1. Endogenous Nitric Oxide Modulates Acetylcholine-induced Edema and Vasoconstriction in Isolated Perfused Rabbit Lungs
      A. DELAUNOIS, P. GUSTIN and M. ANSAY
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 589-597;

  8. DeMattos, S B

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  9. Dent, G

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  10. Desai, K H

    1. Colchicine and cytochalasin B enhance cyclic AMP accumulation via postreceptor actions.
      J R Jasper, S R Post, K H Desai, P A Insel and D Bernstein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 937-942;

  11. Do, M L

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  12. Drewe, J

    1. Enteral absorption of octreotide: modulation of intestinal permeability by distinct carbohydrates.
      G Fricker and J Drewe
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 826-832;

  13. Dulmet, E

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

E

  1. Eckert, R

    1. Inhibition of L-type calcium currents in guinea pig ventricular myocytes by the kappa-opioid agonist U50488H does not involve binding to opiate receptors.
      J Utz, R Eckert and W Trautwein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 627-633;

  2. Edwards, L A

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  3. Edwards, M A

    1. Effects of N-methyl-D-aspartate antagonists in rats discriminating different doses of cocaine: comparison with direct and indirect dopamine agonists.
      K M Kantak, M A Edwards and R D Spealman
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 657-665;

  4. Empfield, J R

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

F

  1. Ferrara, N

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  2. Forenza, S

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  3. Fricker, G

    1. Enteral absorption of octreotide: modulation of intestinal permeability by distinct carbohydrates.
      G Fricker and J Drewe
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 826-832;

  4. Friedman, H

    1. delta 9-Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits.
      W Zhu, T Igarashi, H Friedman and T W Klein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1001-1007;

  5. Fujimoto, J M

    1. Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors.
      P Killian, B B Holmes, A E Takemori, P S Portoghese and J M Fujimoto
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 730-734;

  6. Fukuhara, N

    1. Involvement of dopamine, N-methyl-D-aspartate and sigma receptor mechanisms in methamphetamine-induced anticipatory activity rhythm in rats.
      S Shibata, M Ono, N Fukuhara and S Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 688-694;

G

  1. Galloway, M P

    1. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors.
      C W Aretha, A Sinha and M P Galloway
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 609-613;

  2. Gascard, J P

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

  3. Gatch, M B

    1. Effects of morphine and ketorolac on thermal allodynia induced by prostaglandin E2 and bradykinin in rhesus monkeys.
      S S Negus, E R Butelman, M B Gatch and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 805-814;

  4. George-Nascimento, C

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  5. Georgic, L M

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  6. Glavin, G B

    1. Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats.
      M A Carlisle, D D Smyth and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 598-601;
    2. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats.
      G B Glavin, M A Carlisle and D D Smyth
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 741-744;

  7. Gorenne, I

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

  8. Gough, B

    1. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects.
      P Clausing, B Gough, R R Holson, W Slikker and J F Bowyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 614-621;

  9. Graham, J H

    1. The effect of cocaine and other local anesthetics on central dopaminergic neurotransmission.
      J H Graham, J R Maher and S E Robinson
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 707-717;

  10. Grélot, L

    1. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
      S Milano, P Blower, D Romain and L Grélot
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 951-961;

  11. Griffith, R C

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  12. Guia, A

    1. Effects of phenamil on potassium and calcium channels of guinea pig ventricular myocytes.
      A Guia, N Leblanc and R Bose
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 649-656;

  13. Gustin, P

    1. Endogenous nitric oxide modulates acetylcholine-induced edema and vasoconstriction in isolated perfused rabbit lungs.
      A Delaunois, P Gustin and M Ansay
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 559-597;

  14. GUSTIN, P.

    1. Endogenous Nitric Oxide Modulates Acetylcholine-induced Edema and Vasoconstriction in Isolated Perfused Rabbit Lungs
      A. DELAUNOIS, P. GUSTIN and M. ANSAY
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 589-597;

H

  1. Hales, T G

    1. Modulation of the GABAA receptor by propofol is independent of the gamma subunit.
      M V Jones, N L Harrison, D B Pritchett and T G Hales
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 962-968;

  2. Halterman, T J

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  3. Hammarlund-Udenaes, M

    1. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.
      G Movin-Osswald and M Hammarlund-Udenaes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 921-927;

  4. Harris, E W

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  5. Harrison, N L

    1. Modulation of the GABAA receptor by propofol is independent of the gamma subunit.
      M V Jones, N L Harrison, D B Pritchett and T G Hales
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 962-968;

  6. Hasegawa, H

    1. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries.
      Y Matsuoka, H Hasegawa, S Okuda, T Muraki, T Uruno and K Kubota
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 602-608;

  7. Heffner, T G

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  8. Hexum, T D

    1. Neuropeptide Y (18-36) modulates chromaffin cell catecholamine secretion by blocking the nicotinic receptor ion channel.
      J Zheng, R A Morrisett, J Zhu and T D Hexum
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 891-897;

  9. Hiraoka, A

    1. Enhancement of tobramycin binding to rat renal brush border membrane by vancomycin.
      Y Yano, A Hiraoka and T Oguma
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 695-699;

  10. Holmes, B B

    1. Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors.
      P Killian, B B Holmes, A E Takemori, P S Portoghese and J M Fujimoto
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 730-734;

  11. Holson, R R

    1. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects.
      P Clausing, B Gough, R R Holson, W Slikker and J F Bowyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 614-621;

  12. Hong, J S

    1. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality.
      D M Bronstein and J S Hong
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 943-950;

  13. Houston, J B

    1. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
      E I Ashforth, D J Carlile, R Chenery and J B Houston
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 761-766;

  14. Howe, B B

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  15. Hull, W

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

I

  1. Igarashi, T

    1. delta 9-Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits.
      W Zhu, T Igarashi, H Friedman and T W Klein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1001-1007;

  2. Insel, P A

    1. Colchicine and cytochalasin B enhance cyclic AMP accumulation via postreceptor actions.
      J R Jasper, S R Post, K H Desai, P A Insel and D Bernstein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 937-942;

  3. Irwin, R P

    1. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons.
      G M Yan, R P Irwin, S Z Lin, M Weller, K A Wood and S M Paul
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 983-990;

  4. Ishima, T

    1. Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.
      F Ueda, K Ban and T Ishima
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 815-819;

  5. Iwamoto, Y

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

J

  1. Jasper, J R

    1. Colchicine and cytochalasin B enhance cyclic AMP accumulation via postreceptor actions.
      J R Jasper, S R Post, K H Desai, P A Insel and D Bernstein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 937-942;

  2. Jones, M V

    1. Modulation of the GABAA receptor by propofol is independent of the gamma subunit.
      M V Jones, N L Harrison, D B Pritchett and T G Hales
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 962-968;

K

  1. Kaiser, F C

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  2. Kamei, J

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  3. Kaminski, D L

    1. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes.
      A P Li, A Rasmussen, L Xu and D L Kaminski
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 673-677;

  4. Kantak, K M

    1. Effects of N-methyl-D-aspartate antagonists in rats discriminating different doses of cocaine: comparison with direct and indirect dopamine agonists.
      K M Kantak, M A Edwards and R D Spealman
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 657-665;

  5. Kasuya, Y

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  6. Katofiasc, M A

    1. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat.
      K B Thor and M A Katofiasc
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1014-1024;

  7. Kelly, J J

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  8. Killian, P

    1. Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors.
      P Killian, B B Holmes, A E Takemori, P S Portoghese and J M Fujimoto
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 730-734;

  9. Klein, T W

    1. delta 9-Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits.
      W Zhu, T Igarashi, H Friedman and T W Klein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1001-1007;

  10. Konkoy, C S

    1. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.
      S M Waters, C S Konkoy and T P Davis
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 783-789;

  11. Kreiss, D S

    1. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo.
      D S Kreiss and I Lucki
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 866-876;

  12. Kubota, K

    1. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries.
      Y Matsuoka, H Hasegawa, S Okuda, T Muraki, T Uruno and K Kubota
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 602-608;

L

  1. Labat, C

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

  2. Landino, P

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  3. Lark, L A

    1. Cardiovascular effects after the intracerebroventricular administration of peptide and nonpeptide angiotensin antagonists in Dahl salt-sensitive rats.
      L A Lark, S M Wappel and J A Weyhenmeyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 745-751;

  4. Latinne, D

    1. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects.
      G Lhoëst, R K Verbeeck, N Maton, P Muthelet and D Latinne
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 622-626;

  5. Leblanc, N

    1. Effects of phenamil on potassium and calcium channels of guinea pig ventricular myocytes.
      A Guia, N Leblanc and R Bose
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 649-656;

  6. Lefebvre, R A

    1. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon.
      M R Briejer, G J Veen, L M Akkermans, R A Lefebvre and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 641-648;

  7. Lhoëst, G

    1. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects.
      G Lhoëst, R K Verbeeck, N Maton, P Muthelet and D Latinne
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 622-626;

  8. Li, A P

    1. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes.
      A P Li, A Rasmussen, L Xu and D L Kaminski
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 673-677;

  9. Lin, S Z

    1. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons.
      G M Yan, R P Irwin, S Z Lin, M Weller, K A Wood and S M Paul
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 983-990;

  10. Littarru, G P

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  11. Lucki, I

    1. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo.
      D S Kreiss and I Lucki
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 866-876;

  12. Luthin, G R

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

M

  1. MacKenzie, R G

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  2. Maher, J R

    1. The effect of cocaine and other local anesthetics on central dopaminergic neurotransmission.
      J H Graham, J R Maher and S E Robinson
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 707-717;

  3. Malmberg, A

    1. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides.
      A Malmberg and N Mohell
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 790-797;

  4. Mamber, S W

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  5. Marks, M J

    1. Sodium channel blockers partially inhibit nicotine-stimulated 86Rb+ efflux from mouse brain synaptosomes.
      M J Marks, A E Bullock and A C Collins
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 833-841;

  6. Maton, N

    1. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects.
      G Lhoëst, R K Verbeeck, N Maton, P Muthelet and D Latinne
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 622-626;

  7. Matsuoka, Y

    1. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries.
      Y Matsuoka, H Hasegawa, S Okuda, T Muraki, T Uruno and K Kubota
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 602-608;

  8. Meltzer, L T

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  9. Mikkilineni, A B

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  10. Milano, S

    1. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
      S Milano, P Blower, D Romain and L Grélot
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 951-961;

  11. Misawa, M

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  12. Mohell, N

    1. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides.
      A Malmberg and N Mohell
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 790-797;

  13. Morrisett, R A

    1. Neuropeptide Y (18-36) modulates chromaffin cell catecholamine secretion by blocking the nicotinic receptor ion channel.
      J Zheng, R A Morrisett, J Zhu and T D Hexum
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 891-897;

  14. Moss, D E

    1. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
      G Pacheco, R Palacios-Esquivel and D E Moss
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 767-770;

  15. Movin-Osswald, G

    1. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.
      G Movin-Osswald and M Hammarlund-Udenaes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 921-927;

  16. Muraki, T

    1. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries.
      Y Matsuoka, H Hasegawa, S Okuda, T Muraki, T Uruno and K Kubota
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 602-608;

  17. Murray, R J

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  18. Muthelet, P

    1. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects.
      G Lhoëst, R K Verbeeck, N Maton, P Muthelet and D Latinne
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 622-626;

N

  1. Nagase, H

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  2. Nathaniel, P

    1. Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons.
      W X Shi, P Nathaniel and B S Bunney
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 735-740;

  3. Negus, S S

    1. Effects of morphine and ketorolac on thermal allodynia induced by prostaglandin E2 and bradykinin in rhesus monkeys.
      S S Negus, E R Butelman, M B Gatch and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 805-814;

  4. Nicholson, C D

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  5. Ninteman, F W

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  6. Nishio, S J

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  7. Norel, X

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

O

  1. Oguma, T

    1. Enhancement of tobramycin binding to rat renal brush border membrane by vancomycin.
      Y Yano, A Hiraoka and T Oguma
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 695-699;

  2. Ohnmacht, C J

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  3. Ohsawa, M

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  4. Okuda, S

    1. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries.
      Y Matsuoka, H Hasegawa, S Okuda, T Muraki, T Uruno and K Kubota
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 602-608;

  5. Ono, M

    1. Involvement of dopamine, N-methyl-D-aspartate and sigma receptor mechanisms in methamphetamine-induced anticipatory activity rhythm in rats.
      S Shibata, M Ono, N Fukuhara and S Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 688-694;

  6. Oradei, A

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

P

  1. Pacheco, G

    1. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
      G Pacheco, R Palacios-Esquivel and D E Moss
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 767-770;

  2. Pack, E J

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  3. Palacios-Esquivel, R

    1. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
      G Pacheco, R Palacios-Esquivel and D E Moss
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 767-770;

  4. Palmer, G C

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  5. Paul, S M

    1. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons.
      G M Yan, R P Irwin, S Z Lin, M Weller, K A Wood and S M Paul
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 983-990;

  6. Pettinger, S J

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  7. Piffeteau, A

    1. Nitric oxide formation during the cytochrome P-450-dependent reductive metabolism of 18-nitro-oxyandrostenedione.
      M Delaforge, A Piffeteau, J L Boucher and A Viger
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 634-640;

  8. Plotkine, M

    1. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
      F Stain, M J Barjavel, P Sandouk, M Plotkine, J M Scherrmann and H N Bhargava
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 852-857;

  9. Pontari, M A

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

  10. Portoghese, P S

    1. Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors.
      P Killian, B B Holmes, A E Takemori, P S Portoghese and J M Fujimoto
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 730-734;

  11. Post, S R

    1. Colchicine and cytochalasin B enhance cyclic AMP accumulation via postreceptor actions.
      J R Jasper, S R Post, K H Desai, P A Insel and D Bernstein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 937-942;

  12. Premkumar, L S

    1. Blockade of a resting potassium channel and modulation of synaptic transmission by ecstasy in the hippocampus.
      L S Premkumar and G P Ahern
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 718-722;

  13. Pritchett, D B

    1. Modulation of the GABAA receptor by propofol is independent of the gamma subunit.
      M V Jones, N L Harrison, D B Pritchett and T G Hales
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 962-968;

  14. Pussard, G

    1. Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels.
      G Pussard, J P Gascard, I Gorenne, C Labat, X Norel, E Dulmet and C Brink
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 969-975;

R

  1. Randall, S

    1. The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
      J J Anderson, S Randall and T N Chase
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 928-936;

  2. Rasmussen, A

    1. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes.
      A P Li, A Rasmussen, L Xu and D L Kaminski
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 673-677;

  3. Read, L C

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  4. Rengo, F

    1. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress.
      N Ferrara, P Abete, G Ambrosio, P Landino, P Caccese, P Cirillo, A Oradei, G P Littarru, M Chiariello and F Rengo
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 858-865;

  5. Robinson, S E

    1. The effect of cocaine and other local anesthetics on central dopaminergic neurotransmission.
      J H Graham, J R Maher and S E Robinson
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 707-717;

  6. Romain, D

    1. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
      S Milano, P Blower, D Romain and L Grélot
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 951-961;

  7. Rosenzweig-Lipson, S

    1. Modification of the behavioral effects of (+/-)BAY k 8644, cocaine and d-amphetamine by L-type calcium channel blockers in squirrel monkeys.
      S Rosenzweig-Lipson and J E Barrett
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 842-851;

  8. Rosser, M P

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  9. Rudin, M

    1. Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke.
      A Sauter and M Rudin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1008-1013;

  10. Ruggieri, M R

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

  11. Rugsley, T A

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  12. Russell, K

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

S

  1. Saitoh, A

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  2. Sandouk, P

    1. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
      F Stain, M J Barjavel, P Sandouk, M Plotkine, J M Scherrmann and H N Bhargava
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 852-857;

  3. Sauter, A

    1. Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke.
      A Sauter and M Rudin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1008-1013;

  4. Scherrmann, J M

    1. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
      F Stain, M J Barjavel, P Sandouk, M Plotkine, J M Scherrmann and H N Bhargava
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 852-857;

  5. Schuurkes, J A

    1. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon.
      M R Briejer, G J Veen, L M Akkermans, R A Lefebvre and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 641-648;

  6. Serpa, K A

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  7. Shahid, M

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  8. Sheldon, J H

    1. Acute administration of 17 beta-estradiol inhibits calcium currents in isolated guinea pig detrusor myocytes.
      J H Sheldon and T M Argentieri
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 723-729;

  9. Shi, W X

    1. Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons.
      W X Shi, P Nathaniel and B S Bunney
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 735-740;

  10. Shibata, S

    1. Involvement of dopamine, N-methyl-D-aspartate and sigma receptor mechanisms in methamphetamine-induced anticipatory activity rhythm in rats.
      S Shibata, M Ono, N Fukuhara and S Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 688-694;

  11. Shih, Y H

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  12. Sinha, A

    1. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors.
      C W Aretha, A Sinha and M P Galloway
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 609-613;

  13. Slikker, W

    1. Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects.
      P Clausing, B Gough, R R Holson, W Slikker and J F Bowyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 614-621;

  14. Smyth, D D

    1. Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats.
      M A Carlisle, D D Smyth and G B Glavin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 598-601;
    2. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats.
      G B Glavin, M A Carlisle and D D Smyth
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 741-744;

  15. Smyth, R J

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

  16. Spealman, R D

    1. Effects of N-methyl-D-aspartate antagonists in rats discriminating different doses of cocaine: comparison with direct and indirect dopamine agonists.
      K M Kantak, M A Edwards and R D Spealman
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 657-665;

  17. Spiers, I

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  18. Stagnitto, M L

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  19. Stain, F

    1. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
      F Stain, M J Barjavel, P Sandouk, M Plotkine, J M Scherrmann and H N Bhargava
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 852-857;

  20. Stow, R B

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  21. Strand, J C

    1. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia.
      G C Palmer, E C Cregan, A R Borrelli, E W Harris, M L Stagnitto, P Colombo, F C Kaiser, R J Murray, R C Griffith and J C Strand
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 991-1000;

  22. Styne, D

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  23. Suzuki, T

    1. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
      J Kamei, M Ohsawa, A Saitoh, Y Iwamoto, T Suzuki, M Misawa, H Nagase and Y Kasuya
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 700-706;

  24. Sweeney, K R

    1. The influence of protein binding on the elimination of acetazolamide by the isolated perfused rat kidney: evidence of albumin-mediated tubular secretion.
      D R Taft and K R Sweeney
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 752-760;

T

  1. Taft, D R

    1. The influence of protein binding on the elimination of acetazolamide by the isolated perfused rat kidney: evidence of albumin-mediated tubular secretion.
      D R Taft and K R Sweeney
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 752-760;

  2. Takemori, A E

    1. Cold water swim stress- and delta-2 opioid-induced analgesia are modulated by spinal gamma-aminobutyric acidA receptors.
      P Killian, B B Holmes, A E Takemori, P S Portoghese and J M Fujimoto
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 730-734;

  3. Tarantal, A F

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  4. Thor, K B

    1. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat.
      K B Thor and M A Katofiasc
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1014-1024;
    2. Pharmacological analysis of the noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat.
      H Danuser, K Bemis and K B Thor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 820-825;

  5. Trainor, D A

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

  6. Trautwein, W

    1. Inhibition of L-type calcium currents in guinea pig ventricular myocytes by the kappa-opioid agonist U50488H does not involve binding to opiate receptors.
      J Utz, R Eckert and W Trautwein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 627-633;

U

  1. Ueda, F

    1. Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.
      F Ueda, K Ban and T Ishima
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 815-819;

  2. Ueda, Y

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  3. Uruno, T

    1. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries.
      Y Matsuoka, H Hasegawa, S Okuda, T Muraki, T Uruno and K Kubota
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 602-608;

  4. Utz, J

    1. Inhibition of L-type calcium currents in guinea pig ventricular myocytes by the kappa-opioid agonist U50488H does not involve binding to opiate receptors.
      J Utz, R Eckert and W Trautwein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 627-633;

V

  1. van Amsterdam, R G

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  2. van Leeuwen, D H

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  3. VanRollins, M

    1. Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting thromboxane synthesis.
      M VanRollins
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 798-804;

  4. Veen, G J

    1. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon.
      M R Briejer, G J Veen, L M Akkermans, R A Lefebvre and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 641-648;

  5. Verbeeck, R K

    1. The in vitro immunosuppressive activity of the C15-demethylated metabolite of FK-506 is governed by ring- and open-chain tautomerism effects.
      G Lhoëst, R K Verbeeck, N Maton, P Muthelet and D Latinne
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 622-626;

  6. Viger, A

    1. Nitric oxide formation during the cytochrome P-450-dependent reductive metabolism of 18-nitro-oxyandrostenedione.
      M Delaforge, A Piffeteau, J L Boucher and A Viger
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 634-640;

W

  1. Wang, J

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

  2. Wang, P

    1. Human prostate muscarinic receptor subtypes.
      M R Ruggieri, M D Colton, P Wang, J Wang, R J Smyth, M A Pontari and G R Luthin
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 976-982;

  3. Wappel, S M

    1. Cardiovascular effects after the intracerebroventricular administration of peptide and nonpeptide angiotensin antagonists in Dahl salt-sensitive rats.
      L A Lark, S M Wappel and J A Weyhenmeyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 745-751;

  4. Watanabe, S

    1. Involvement of dopamine, N-methyl-D-aspartate and sigma receptor mechanisms in methamphetamine-induced anticipatory activity rhythm in rats.
      S Shibata, M Ono, N Fukuhara and S Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 688-694;

  5. Waters, S M

    1. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.
      S M Waters, C S Konkoy and T P Davis
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 783-789;

  6. Weir, A J

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  7. Weller, M

    1. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons.
      G M Yan, R P Irwin, S Z Lin, M Weller, K A Wood and S M Paul
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 983-990;

  8. Weyhenmeyer, J A

    1. Cardiovascular effects after the intracerebroventricular administration of peptide and nonpeptide angiotensin antagonists in Dahl salt-sensitive rats.
      L A Lark, S M Wappel and J A Weyhenmeyer
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 745-751;

  9. Whetzel, S Z

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
      T A Rugsley, M D Davis, H C Akunne, L W Cooke, S Z Whetzel, R G MacKenzie, Y H Shih, D H van Leeuwen, S B DeMattos and L M Georgic
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 898-911;

  10. Whitsett, J A

    1. Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys.
      L A Edwards, L C Read, S J Nishio, A J Weir, W Hull, S Barry, D Styne, J A Whitsett, A F Tarantal and C George-Nascimento
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1025-1032;

  11. Wiley, J N

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  12. Wise, L D

    1. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
      L T Meltzer, C L Christoffersen, A E Corbin, F W Ninteman, K A Serpa, J N Wiley, L D Wise and T G Heffner
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 912-920;

  13. Wong, H

    1. Tubulin polymerization by paclitaxel (taxol) phosphate prodrugs after metabolic activation with alkaline phosphatase.
      S W Mamber, A B Mikkilineni, E J Pack, M P Rosser, H Wong, Y Ueda and S Forenza
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 877-883;

  14. Wood, K A

    1. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons.
      G M Yan, R P Irwin, S Z Lin, M Weller, K A Wood and S M Paul
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 983-990;

  15. Woods, J H

    1. Effects of morphine and ketorolac on thermal allodynia induced by prostaglandin E2 and bradykinin in rhesus monkeys.
      S S Negus, E R Butelman, M B Gatch and J H Woods
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 805-814;

X

  1. Xiao, W H

    1. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats.
      W H Xiao and G J Bennett
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 666-672;

  2. Xu, L

    1. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes.
      A P Li, A Rasmussen, L Xu and D L Kaminski
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 673-677;

Y

  1. Yan, G M

    1. Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons.
      G M Yan, R P Irwin, S Z Lin, M Weller, K A Wood and S M Paul
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 983-990;

  2. Yano, Y

    1. Enhancement of tobramycin binding to rat renal brush border membrane by vancomycin.
      Y Yano, A Hiraoka and T Oguma
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 695-699;

  3. Yochim, C L

    1. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
      B B Howe, T J Halterman, C L Yochim, M L Do, S J Pettinger, R B Stow, C J Ohnmacht, K Russell, J R Empfield and D A Trainor
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 884-890;

Z

  1. Zaagsma, J

    1. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
      C D Nicholson, M Shahid, J Bruin, E Barron, I Spiers, J de Boer, R G van Amsterdam, J Zaagsma, J J Kelly and G Dent
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 678-687;

  2. Zheng, J

    1. Neuropeptide Y (18-36) modulates chromaffin cell catecholamine secretion by blocking the nicotinic receptor ion channel.
      J Zheng, R A Morrisett, J Zhu and T D Hexum
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 891-897;

  3. Zhu, J

    1. Neuropeptide Y (18-36) modulates chromaffin cell catecholamine secretion by blocking the nicotinic receptor ion channel.
      J Zheng, R A Morrisett, J Zhu and T D Hexum
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 891-897;

  4. Zhu, W

    1. delta 9-Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits.
      W Zhu, T Igarashi, H Friedman and T W Klein
      Journal of Pharmacology and Experimental Therapeutics August 1995, 274 (2) 1001-1007;
Back to top

In this issue

Advertisement